{
  "ticker": "LLY",
  "target_date": "2025-11-27",
  "actual_date": "2025-11-26",
  "collected_at": "2025-12-08T12:35:24.451039",
  "price": {
    "open": 1102.0,
    "high": 1111.99,
    "low": 1098.1,
    "close": 1104.3399658203125,
    "volume": 3093700,
    "change_1d_pct": -0.5,
    "change_7d_pct": 8.09,
    "change_30d_pct": 33.8
  },
  "technicals": {
    "rsi_14": 87.34,
    "sma_20": 989.66,
    "sma_50": 875.24,
    "macd": 65.974,
    "macd_signal": 58.861,
    "macd_histogram": 7.113,
    "bb_upper": 1146.68,
    "bb_lower": 832.64,
    "price_vs_sma20_pct": 11.59,
    "price_vs_sma50_pct": 26.18,
    "volume_ratio": 0.65
  },
  "fundamentals": {
    "market_cap": 891862450176,
    "pe_ratio": 48.744488,
    "forward_pe": 43.904457,
    "price_to_book": 37.457645,
    "price_to_sales": 15.009517,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.53,
    "pct_from_52w_low": 59.49
  },
  "macro": {
    "spy": {
      "price": 679.68,
      "change_1d_pct": 0.69,
      "change_7d_pct": 2.97
    },
    "vix": {
      "level": 17.19,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.0
    },
    "dollar_index": {
      "level": 99.6
    },
    "gold": {
      "price": 4165.2
    },
    "regime": "BULL_LOW_VOL"
  },
  "news": [
    {
      "headline": "Novo Nordisk or Pfizer: Which Healthcare Giant Is the Better Bet?",
      "source": "Yahoo",
      "datetime": 1764262260,
      "summary": "PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare giants.",
      "url": "https://finnhub.io/api/news?id=2961f9d90368cc8e476d3dbafdda6ed6765fe87f8137b478b2dc847e4606d222"
    },
    {
      "headline": "Novo Nordisk Seeks Extra-Fast Nod From FDA for Higher Dose of Wegovy",
      "source": "Yahoo",
      "datetime": 1764260640,
      "summary": "NVO seeks an expedited FDA review for a higher 7.2 mg dose of Wegovy after strong weight-loss results in its STEP UP study.",
      "url": "https://finnhub.io/api/news?id=a33491673345183c33592b13d6bb2c6642734382180936bbc3c25f84931862a5"
    },
    {
      "headline": "Eli Lilly\u2019s Stock Price Has Fattened Up Like a Thanksgiving Turkey. Time to (Options) Collar That Green!",
      "source": "Yahoo",
      "datetime": 1764246602,
      "summary": "As Eli Lilly makes history by joining the $1 trillion club, here\u2019s how you can position for its next move.",
      "url": "https://finnhub.io/api/news?id=ea516e209e1d8e27e74db79a280b4cfc9007f8bf3bb2939a88c4818f85be9bce"
    },
    {
      "headline": "Prediction: This Growth Stock Could Hit a $2 Trillion Valuation by 2031",
      "source": "Yahoo",
      "datetime": 1764245880,
      "summary": "It's not only tech companies that can get to that market valuation.",
      "url": "https://finnhub.io/api/news?id=24e3435ec0c8e97ea7770b7c622cc5adaadc798272e09fd7d52ca913c9d7066d"
    },
    {
      "headline": "Thanksgiving: Top 10 Most Innovative BioPharma Drugs In Phase 3",
      "source": "SeekingAlpha",
      "datetime": 1764228044,
      "summary": "Highlighting 10 innovative late-stage BioPharma drugs with the potential to reshape treatment paradigms and industry dynamics. Click here to read our picks.",
      "url": "https://finnhub.io/api/news?id=957425ce99f347f8ced0b3b60d44d11301701358932b1cbe7eb457febabbcede"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-11-26",
      "description": "xslF345X05/form4-11262025_041104.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000093/xslF345X05/form4-11262025_041104.xml"
    },
    {
      "form": "4",
      "date": "2025-11-26",
      "description": "xslF345X05/form4-11262025_041101.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000092/xslF345X05/form4-11262025_041101.xml"
    },
    {
      "form": "4",
      "date": "2025-11-25",
      "description": "xslF345X05/form4-11252025_041101.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000089/xslF345X05/form4-11252025_041101.xml"
    },
    {
      "form": "4",
      "date": "2025-11-24",
      "description": "xslF345X05/form4-11242025_041101.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000087/xslF345X05/form4-11242025_041101.xml"
    },
    {
      "form": "8-K",
      "date": "2025-11-21",
      "description": "lly-20251118.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000271/lly-20251118.htm"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}